CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Climb Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Climb Bio Inc
20 WILLIAM STREET, SUITE 145
Phone: (425) 276-2300p:425 276-2300 WELLESLEY HILLS, MA  02481  United States Ticker: CLYMCLYM

Business Summary
Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Andrew D.Levin 47 8/26/2024 10/1/2018
President, Chief Executive Officer, Director Aoife M.Brennan 48 6/27/2024 6/27/2024
Principal Financial Officer, Chief Operating Officer Brett I.Kaplan 50 8/26/2024 8/26/2024
5 additional Officers and Directors records available in full report.

Business Names
Business Name
CLYM
Eliem Therapeutics (UK) Ltd. (England and Wales)
ELYM
Tenet Medicines, Inc.

General Information
Number of Employees: 9 (As of 12/31/2023)
Outstanding Shares: 67,223,760 (As of 11/7/2024)
Shareholders: 15
Stock Exchange: NASD
Federal Tax Id: 832273741
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024